Northland Securities reaffirmed their corporate rating on shares of Beximco Pharmaceuticals Limited (LON:BXP) in a research note published on Tuesday.

Beximco Pharmaceuticals Limited (LON BXP) traded up GBX 1.40 ($0.02) on Tuesday, reaching GBX 59.90 ($0.79). 2,286 shares of the company’s stock traded hands, compared to its average volume of 79,301. Beximco Pharmaceuticals Limited has a 12 month low of GBX 45.05 ($0.59) and a 12 month high of GBX 71.75 ($0.94).

ILLEGAL ACTIVITY NOTICE: “Beximco Pharmaceuticals Limited (BXP) Earns Corporate Rating from Northland Securities” was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this news story on another domain, it was stolen and republished in violation of U.S. and international copyright laws. The original version of this news story can be accessed at

Beximco Pharmaceuticals Limited Company Profile

Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulation products and active pharmaceutical ingredients. It offers allergic disorder, analgesic and antipyretic, anti-infective, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, intravenous fluid, muscloskeletal, oncology, respiratory, skin care, vitamin and mineral supplement, and other products.

Receive News & Ratings for Beximco Pharmaceuticals Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beximco Pharmaceuticals Limited and related companies with Analyst Ratings Network's FREE daily email newsletter.